How much warfarin is enough in APS related thrombosis?

Thrombosis Research

Volumn 114, Issue 5-6 SPEC. ISS., 2004, Pages 435-442

  Erkan, Doruk ^a   Lockshin, Michael D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

APS; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CARBAMAZEPINE; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; COTRIMOXAZOLE; CYCLOSPORIN; DICLOXACILLIN; ERYTHROMYCIN; ETRETINATE; FLUCONAZOLE; GRISEOFULVIN; ISONIAZID; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; OMEPRAZOLE; PARACETAMOL; PHENYLBUTAZONE; PHOSPHOLIPID ANTIBODY; PIROXICAM; PROPRANOLOL; RIFAMPICIN; SUCRALFATE; SULFINPYRAZONE; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BIRTH WEIGHT; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; EPIPHYSIS; EYE DISEASE; FETUS WASTAGE; HEARING LOSS; HUMAN; HYPOPLASIA; KIDNEY DISEASE; LEG ULCER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; THROMBOSIS; TREATMENT INDICATION; VALVULAR HEART DISEASE; VEIN THROMBOSIS;

EID: 7244242661     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.010     Document Type: Article

References (59)

1. Brey R.L., Chapman J., Levine S.R., Ruiz-Irastorza G., Derksen R.H.W.M., Khamashta M., et al. Stroke and antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus. 12:2003;508-513
2. Meroni P.L., Moia M., Derksen R.H.W.M., Tincani A., McIntyre J.A., Arnout J.M.M.C., et al. Venous thromboembolism in the antiphospholipid syndrome; management guidelines for secondary prophylaxis. Lupus. 12:2003;504-507
3. Sullivan R. Rats. Observations on the history and habitat of the city's most unwanted inhabitants. 2004;122-123 Bloomsbury, New York
4. Shapiro S.S. Treating thrombosis in the 21st century. N. Engl. J. Med. 349(18):2003;1762-1764. [editorial]
5. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121:1994;676-683
6. Package insert for Bristol-Myers Squibb Coumadin, Copyright 2002, 6572-01/Rev. June 2002.
7. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104(4):1998;332-338
8. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340(12):1999;901-907
9. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95(3):1993;315-328
10. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 348(9025):1996;423-428
11. Hirsh J., Kearon C., Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch. Intern. Med. 157(19):1997;2174-2177
12. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch. Intern. Med. 153:1993;1557-1562
13. al-Sayegh F.A., Ensworth S., Huang S., Stein H.B., Klinkhoff A.V. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J. Rheumatol. 24:1997;1716-1718
14. Hull R., Hirsh J., Jay R., Carter C., England C., Gent M., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N. Engl. J. Med. 307:1982;1676-1681
15. Rosove M.H., Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117:1992;303-308
16. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332:1995;993-997
17. Derksen R.H., de Groot P.G., Kater L., Nieuwenhuis H.K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann. Rheum. Dis. 52:1993;689-692
18. Ruiz-Irastorza G., Khamashta M.A., Hunt B.J., Escudero A., Cuadrado M.J., Hughes G.R. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch. Intern. Med. 162:2002;1164-1169
19. Makris M., Watson H.G. The management of coumarin-induced over-anticoagulation. Br. J. Haematol. 114:2001;271-280
20. Fihn S.D., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann. Intern. Med. 118:1993;511-520
21. Oldenburg J., Kriz K., Wuillemin W.A., Maly F.E., von Felten A., Siegemund A., et al. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb. Haemost. 85:2001;454-457
22. Hirsh J., Dalen J., Guyatt G. American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest. 119(Suppl. 1):2001;1S-2S
23. Fitzmaurice D.A., Machin S.J. British Society of Haematology Task Force for Haemostasis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. BMJ. 323(7319):2001;985-989
24. Hall J.G., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med. 68:1980;122-140
25. Vilela V.S., de Jesus N.R., Levy R.A. Prevention of thrombosis during pregnancy. Isr. Med. Assoc. J. 4(10):2002 (Oct.);794-797
26. Pauzner R., Dulitzki M., Langevitz P., Livneh A., Kenett R., Mary A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb. Haemost. 86:2001;1379-1384
27. Erkan D., Sammaritano L.R., Levy R.A., Harrison M.J., Peterson M., Yazici Y., et al. APLASA Study update: primary thrombosis in asymptomatic aPL positive patients with aspirin (ASA). Thromb Res. 2004;. in press
28. Khamashta M.A. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J. Autoimmun. 15(2):2000 (Sep.);249-253
29. Olguin L., Calleja C., Hernandez C., Rangel C., Jara J. Primary antiphospholipid syndrome nephropathy despite anticoagulation. Arthritis Rheum. 48:2003;s359. [abst]
30. Erkan D., Roman M.J., Tenedios F., Lockshin M.D. Cardiac involvement in the antiphospholipid syndrome. Doria A., Pauletto P. The heart in systemic autoimmune diseases. Handbook of Systemic Autoimmune Diseases. vol. 1:2004;213-225 Elsevier, Amsterdam. Chapter 14
31. Agirbasli M.A, Hansen D.E., Byrd B.F. III Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J. Am. Soc. Echocardiogr. 10:1997;877-880
32. Nesher G., Ilanyh J., Rosenmann D., Abraham A.S. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin. Arthritis Rheum. 27:1997;27-35
33. Erkan D., Asherson R.A., Espinosa G., Cervera R., Font J., Piette J.-C., et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann. Rheum. Dis. 62:2003;530-533
34. Silverberg M., Erkan D., Sammaritano L., Lockshin M. Is there a role for non-warfarin agents in the long-term management of antiphospholipid syndrome (APS)? Arthritis Rheum. 48:2003;s357. [abst]
35. Krnic-Barrie S., O'Connor C.R., Looney S.W., Pierangeli S.S., Harris E.N. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157:1997;2101-2108
36. Ginsberg J.S., Wells P.S., Brill-Edwards P., Donovan D., Moffatt K., Johnston M., et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 86:1995;3685-3691
37. Rance A., Emmerich J., Fiessinger J.N. Anticardiolipin antibodies and recurrent thromboembolism. Thromb. Haemost. 77:1997;221-222
38. Prandoni P., Simioni P., Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb. Haemost. 75(5):1996 (May);859
39. Crowther M.A, Ginsberg J.S., Julian J., Denburg J., Hirsh J., Doukekis J., et al. Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349:2003;1133-1138
40. Lockshin M.D., Erkan D. Treatment of the antiphospholipid syndrome. N. Engl. J. Med. 349:2003;1177-1179. [editorial]
41. Linkins L.A., Weitz J.I. New anticoagulants. Semin. Thromb. Hemost. 29:2003;619-631
42. Ridker P.M., Goldhaber S.Z., Glynn R.J. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N. Engl. J. Med. 27(349):2003;2164-2167
43. Girolami A., Zanon E., Zanardi S., Saracino M.A., Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul. Fibrinolysis. 7:1996;497-501
44. Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 80:1992;614-620
45. Erkan D., Yazici Y., Peterson M.G., Sammaritano L., Lockshin M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 41:2002;924-929
46. Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 77:1998;195-207
47. Kearon C. Duration of anticoagulation for venous thromboembolism. J. Thromb. Thrombolysis. 12:2001;59-65
48. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann. Neurol. 42:1997;857-865
49. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. aPL and stroke study (APASS). Lupus. 11:2002;559
50. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. J. Am. Med. Assoc. 291:2004;576-584
51. Derksen R.H., de Groot P.G., Kappelle L.J. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology. 61:2003;111-114
52. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 119(1 Suppl):2001;300S- 320S
53. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143:1996;1-13
54. CAPRIE Steering Committee A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339
55. Hyers T.M. Management of venous thromboembolism: past, present, and future. Arch. Intern. Med. 163:2003;759-768
56. Francis C.W., Berkowitz S.D., Comp P.C., Lieberman J.R., Ginsberg J.S, Paiement G., et al. (EXULT A Study Group). Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl J. Med. 349:2003;1703-1712
57. Schulman S., Wahlander K., Lundstrom T., Clason S.B., Eriksson H., THRIVE III Investigators Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349:2003;1713-1721
58. Salmon J.E., Girardi G. The role of complement in the antiphospholipid syndrome. Curr. Dir. Autoimmun. 7:2004;133-148
59. Roubey R.A. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 48:2003;3004-3008